Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Numares AG cashes in €20m from EIB

The European Investment Bank (EIB) announced to invest up to €20m "quasi-equity" loan in German Numares Health AG. The Regensburg-based...

European VCs join US$105m financing of US Mediar Thx

Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...

Vitestro raises €12m in Series A financing

California-based Sonder Capital led the Series A financing round alongside existing investors and new private investors. According to...

Novo Holdings invests into standardisation of LC-MS-based proteomics

Novo Holdings, the investment arm of Nordisk A/S has invested €40m in the eight-years-old clinical proteomics specialist Ecosep Aps to benefit from...

Ultra-processed foods increase risk for cancer

According to a long-term data from the UK biobank, high consumption of ultra-processed foods are linked to bad health outcomes such as diabetes,-...

Evidence of deliberate climate damage

For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

Collaboration to develop mRNA vaccine against betacoronaviruses

Ethris GmbH a German company specialising in the development of mRNA vaccines, announced their collaboration with DIOSynVax Ltd., an English biotech...